Difference between revisions of "Selenium"

From MagnetoWiki
Jump to navigation Jump to search
(→‎Sodium Selenate: added osmolarity calculations)
(added link to daily show video)
Line 33: Line 33:
  
 
Abdo (1994) reported on the effects of administering sodium selenate in the drinking water for 13 weeks. It was estimated that the "no-observed adverse level" in rat was 0.4 mg/kg per day of sodium selenate for 13 weeks. Doses of 0.6 mg/kg or 1.1 mg/kg  per day for 13 weeks caused changes in mortality, body weight depression, decreased water consumption, and renal papillary lesions. However, these were chronic studies so that rats received a total dose of 54.6 mg/kg or 100.1 mg/kg sodium selenate over 13 weeks.
 
Abdo (1994) reported on the effects of administering sodium selenate in the drinking water for 13 weeks. It was estimated that the "no-observed adverse level" in rat was 0.4 mg/kg per day of sodium selenate for 13 weeks. Doses of 0.6 mg/kg or 1.1 mg/kg  per day for 13 weeks caused changes in mortality, body weight depression, decreased water consumption, and renal papillary lesions. However, these were chronic studies so that rats received a total dose of 54.6 mg/kg or 100.1 mg/kg sodium selenate over 13 weeks.
 +
 +
Aasif Mandvi ran a [http://www.thedailyshow.com/watch/thu-june-14-2012/a-simple-plot story] on selenium pollution of Idaho rivers as a consequence of phosphate mining.
 +
 +
  
 
==References==
 
==References==
Line 43: Line 47:
  
 
Corcoran NM et al. 2010b.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
 
Corcoran NM et al. 2010b.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008
 +
 +
Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. http://www.thedailyshow.com/watch/thu-june-14-2012/a-simple-plot
  
 
Reid ME et al.  2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
 
Reid ME et al.  2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766
  
 
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941
 
van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941

Revision as of 07:46, 17 June 2012

Selenium is an essential micronutrient. Recently, a specific selenium salt, sodium selenate, was discovered to be a specific enhancer of the enzyme protein phosphatase 2A (PP2A). PP2A removes phosphate groups from target proteins, including tau, a protein implicated in Alzheimer’s disease Corcoran 2010a PMID 20537899, van Eersel 2010 PMID 20643941, and many other proteins implicated in the control of cancer (Corcoran 2010b PMID 20648008).

Because phosphatases like PP2A remove phosphate groups that activate other proteins, PP2A can be considered a “brake” on the activity of cells, including neurons involved in learning and memory. We have previously shown that inhibiting phosphatase PP2A with the non-specific blocker okadaic acid increased the strength of learned conditioned taste aversions in rats. In other words, blocking PP2A “cut the brakes” on the learning mechanism, causing the rats to acquire a stronger memory of a toxic fluid (saccharin paired with lithium chloride).

Because sodium selenate can act as an enhancer of PP2A, we hypothesize that administering sodium selenate before a conditioning trial will decrease the strength of conditioned taste aversion learning (i.e., the “brakes” will be enhanced, thus diminishing the learning.)

Sodium Selenate

Sigma-Aldrich S8295-10G $56

CAS Number: 13410-01-0

Linear Formula: Na2SeO4

Molecular Weight: 188.94

EC Number: 236-501-8

MDL number: MFCD00003490

PubChem Substance ID: 24899787


Osmolarity of Na2Se04 at 12 mg/ml (63 mM) = 189 mOsm

So Na2Se04 at 12 mg/ml (63 mM), NaCl at 3.2 mg/ml (55mM) = 300 mOsm

Toxicity of Selenate

Selenium is an essential micronutrient and is naturally found a wide variety of food stuffs. As an antioxidant, it is frequently used to treat, e.g., heavy metal toxicosis or liver disease. The recommended dietary intake for adults is 55 micrograms/day, and selenium supplements of 200-300 micrograms/day have been recommended for prevention of several types of cancer. High doses of 1.5 to 5 mg/ day are associated with adverse effects (Brozmanova 2010, Reid 2004). The chemical form of selenium also contributes to toxicity. The form we will use, sodium selenate (Na2Se04), is well-tolerated in human trials (Corcoran 2010b).

Corcoran (2010a) administered sodium selenate to mice acutely at 12 mg/kg, and chronically at ~192 mg/kg per day in drinking water, and did not report any aversive or toxic effects on the mice. van Eersel (2010) administered sodium selenate to mice chrionically at ~ 1.9 mg/kg per day in drinking water, and also did not report any aversive or toxic effects.

Abdo (1994) reported on the effects of administering sodium selenate in the drinking water for 13 weeks. It was estimated that the "no-observed adverse level" in rat was 0.4 mg/kg per day of sodium selenate for 13 weeks. Doses of 0.6 mg/kg or 1.1 mg/kg per day for 13 weeks caused changes in mortality, body weight depression, decreased water consumption, and renal papillary lesions. However, these were chronic studies so that rats received a total dose of 54.6 mg/kg or 100.1 mg/kg sodium selenate over 13 weeks.

Aasif Mandvi ran a story on selenium pollution of Idaho rivers as a consequence of phosphate mining.


References

Abdo, K.M. 1994. NTP Technical Report on Toxicity Studies of Sodium Selenate and Sodium Selenite (CAS Nos. 13410-01-0 and 10102-18-8) Administered in Drinking Water to F344/N Rats and B6C3F1 Mice. NIH Publication 9a4-3387. National Toxicology Program. Toxicity Report Series Number 38.

Brozmanova et al., 2010. Selenium: a double-edged sword for defense and offence in cancer, Arch. Toxicol. 84:919–938. PMID 20871980.

Corcoran NM, et al., 2010a. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci. 8:1025-33. PMID 20537899

Corcoran NM et al. 2010b. Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer. 103:462-8. PMID 20648008

Mandvi, A. A Simple Plot. The Daily Show with Jon Stewart, aired June 14, 2012. http://www.thedailyshow.com/watch/thu-june-14-2012/a-simple-plot

Reid ME et al. 2004 A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74 PMID 15487766

van Eersel J et al. 2010. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. PNAS 107:13888-93. PMID 20643941